Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Gulf International Bank UK Ltd

Gulf International Bank UK Ltd lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,924 shares of the medical research company’s stock after selling 2,126 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Edwards Lifesciences were worth $3,162,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Clarity Capital Partners LLC raised its stake in Edwards Lifesciences by 16.7% during the third quarter. Clarity Capital Partners LLC now owns 9,169 shares of the medical research company’s stock valued at $605,000 after buying an additional 1,312 shares in the last quarter. Impax Asset Management Group plc raised its stake in Edwards Lifesciences by 66.2% during the third quarter. Impax Asset Management Group plc now owns 12,964 shares of the medical research company’s stock valued at $855,000 after buying an additional 5,164 shares in the last quarter. QRG Capital Management Inc. raised its stake in Edwards Lifesciences by 66.6% during the third quarter. QRG Capital Management Inc. now owns 77,245 shares of the medical research company’s stock valued at $5,097,000 after buying an additional 30,892 shares in the last quarter. Asset Management One Co. Ltd. raised its stake in Edwards Lifesciences by 0.9% during the third quarter. Asset Management One Co. Ltd. now owns 239,392 shares of the medical research company’s stock valued at $15,797,000 after buying an additional 2,188 shares in the last quarter. Finally, National Pension Service raised its stake in Edwards Lifesciences by 9.2% during the third quarter. National Pension Service now owns 1,584,579 shares of the medical research company’s stock valued at $104,566,000 after buying an additional 133,182 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on EW shares. UBS Group cut their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Wells Fargo & Company dropped their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Finally, Royal Bank of Canada dropped their price target on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $65.75 on Thursday. The stock has a fifty day moving average price of $67.75 and a two-hundred day moving average price of $77.18. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a market cap of $39.61 billion, a P/E ratio of 9.49, a PEG ratio of 3.80 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the company posted $0.59 EPS. Research analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,250 shares of company stock valued at $2,746,988. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.